Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Myasthenia Gravis (MG) ModelsAutoimmune Nephropathy modelsAcute Lung Injury ModelsIdiopathic Pulmonary Fibrosis ModelsSjögren’ s Syndrome ModelsSystemic Lupus Erythematosus (SLE) ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsMASH ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Autosomal Dominant Polycystic Kidney Disease (ADPKD)Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Polycystic kidney disease (PKD) is a genetic renal disease characterized by the development of renal fluid-filled cysts, which eventually leads to kidney failure. There are two types of polycystic kidney disease: Autosomal Dominant Polycystic Kidney Disease (ADPKD), the more common form, and Autosomal Recessive Polycystic Kidney Disease (ARPKD), which is much rarer. ADPKD is the most common inherited disorder that typically presents in adults. It is mostly caused by mutations of the PKD1 gene encoding polycystin 1 (PC1), which regulates cellular processes such as fluid transport, differentiation, proliferation, apoptosis and cell adhesion.

 

Tolvaptan has recently been approved as a clinical drug that slows ADPKD progression, potentially through increasing urination and avoiding fluid reabsorption in cysts. Emerging gene therapies have also offered the promise of a complete cure against ADPKD.

 

To accelerate the research and development of these new treatments, GemPharmatech has developed an ADPKD model (Pkd1 flox/flox, Cdh16-CreERT2), in which mouse Pkd1 is conditionally abolished in the tubule epithelium of 3- to 4-week-old mice. These mice exhibited renal disorders, enlarged kidney volume and development of cyst structures after induction, which can be partially relieved by Tolvaptan treatment.

 

Sample Phenotypic Data

● Body weight change

1.jpg

One hundred mg/kg/d tamoxifen was injected into 3-week-old mice, with the first injection denoted as Day 1. In male Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice, a decrease in body weight was observed starting from Day 63. N=3.

 

● Serum BUN and CREA

2.jpg

Serum BUN and CREA level were significantly increased in male Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice, indicating impaired kidney function. N=3

 

● Renal ultrasonography

3.jpg

Renal volume was significantly increased in female Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice. N=3

 

● Kidney Cystic Index of Day92 mice

4.jpg

Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice displayed significant increase in kidney cystic index. N=3

 

● Kidney pathology analysis by HE staining

5.png

Significant pathology phenotypes, including the presence of multiple cysts, protein casts and tubular atrophy were observed in Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice.

 

Sample Efficacy Data

● Study Design

6.png


● Serum BUN and CREA

7.png

At Day 86 and Day 100, 0.1% tolvaptan treatment significantly attenuated the increase of serum BUN and CREA levels in male Pkd1: fl/fl Cdh16-CreERT2: ki/wt model mice. N=5

 

● Renal ultrasonography-male

8.png

At Day 80 and Day 92, compared to Pkd1: fl/fl Cdh16-CreERT2: wt/wt mice, renal volumes were significantly increased in Pkd1: fl/fl Cdh16-CreERT2: ki/wt male mice. 0.1% tolvaptan treatment partially reversed the expansion of kidney volume. N=5

 

● Renal ultrasonography-female

9.png

At Day 65, Day 80 and Day 92, compared to Pkd1: fl/fl Cdh16-CreERT2: wt/wt mice, renal volumes were significantly increased in Pkd1: fl/fl Cdh16-CreERT2: ki/wt male mice. 0.1% tolvaptan treatment partially reversed the expansion of kidney volume at Day 92. N=5

 

● Kidney index of Day103 male mice and Day107 female mice

10.png

Treatment with 0.1% tolvaptan attenuated the increase of kidney index in Pkd1: fl/fl Cdh16-CreERT2: wt/wt mice. N=5